X GEN Congress 2013
18 - 20 March, 2013 Hilton San Diego Resort, San Diego, CA, USA
NGS has enabled faster and cheaper mapping of DNA/RNA, allowing genomic comparisons and accelerating genomic discoveries. Cambridge Healthtech Institute is proud to host the Fourth Annual X-Gen Congress and Expo, which is uniquely designed to cover these technological advances and discover advancing applications. With the focus now on clinical utility, find out why data analysis is the driving force that enables discovery, and is sequencing's strategic step.
Plenary Keynote Session
Plenary Keynote Session
2:00 Chairpersonfs Opening Remarks
2:15 Profiling Dynamic Regulation of the Epigenome Defines Linkages between Metabolism and Breast Cancer
Kevin Gardner, M.D., Ph.D., Senior Investigator and Head,
Transcription Regulation Section, Center for Cancer Research, NCI, NIH, DHHS
New findings linking epigenetic regulation to cellular processes that drive important hallmarks of cancer will be discussed. The broader impact of these findings on defining molecular and genomic mechanisms that uncover important connections between race, obesity and breast cancer will be reviewed.
3:00 Landscape of Somatic Retrotransposition in Human Cancers
Peter J. Park, Ph.D., Associate Professor, Center for
Biomedical Informatics, Harvard Medical School; Informatics Program, Childrenfs
Transposable elements (TEs) comprise close to half of the human genome, and some TE families are still able to copy and insert their sequences into other genomic loci through an RNA-mediated mechanism. We will describe our analysis of somatic retrotransposition events in cancer and their potential role in tumorigenesis, using a computational method called Tea (Transposable Element Analyzer) we developed for detecting TE integration sites at single-nucleotide resolution from paired-end whole-genome sequencing data. We have identified nearly 200 high-confidence somatic TE insertions in the cancer genomes of 43 patients across multiple tumor types, and our integrative analyses with other data types have indicated their potential impact in tumorigenesis. We will give an update on our efforts at characterizing TE activities in a more comprehensive panel of tumor types.
3:45 Afternoon Refreshment Break
4:00 Gene Regulation and Common Disease
John Stamatoyannopoulos, M.D. Associate Professor, Genome Sciences and Medicine, School of Medicine, University of Washington
5:00 Panel Discussion with Plenary Speakers
Moderator: Kevin A. Davies, Ph.D., Editor-in-Chief, Bio-IT World
Thanks to the explosive power of NGS and extraordinary collaborative projects such as ENCODE and TCGA, researchers are gaining important new insights regarding genome function and architecture, including the role of non-coding RNAs and epigenetic modifications in health and disease. In this plenary panel discussion, our opening speakers will discuss the implications of current research and future directions and priorities.
Genome in a Bottle Consortium
Thursday, March 21
7:30 am Consortium Registration
8:30 Genome in a Bottle Consortium
NIST has recently convened the Genome in a Bottle Consortium to develop the reference materials, reference methods, and reference data needed to support confidence in human whole genome variant calls. The work of this consortium will enable translation of sequencing to clinical applications through a community standards development effort.
The consortium will host a morning session to present its work plan, progress at NIST in developing whole-genome reference materials, and updates from each of four working groups: (1) Reference Material (RM) Selection and Design; (2) Measurements for Reference Material Characterization; (3) Bioinformatics, Data Integration and Data Representation; (4) Performance Metrics and Figures of Merit.
NGS for Drugs, Patients and Clinical Trials
Designed for drug developers to explore the unparalleled advantages of NGS technologies for translational research, while addressing common challenges.
Learn more at healthtech.com/ngs-drug-development
Applying NGS and Data Analysis
Hear first-hand what thought leaders are saying about the use of NGS over the past two years, as well as their perspective on where NGS will take us in the future.
Detecting Sense-Antisense Transcripts Differentially Regulated by Androgens in Prostate Cancer Cells
Melanie Lehman, Ph.D., Research Scientist, Australian Prostate Cancer Research Centre, Queensland University of Technology
To view the poster, please click here.
In less than five years next-generation sequencing has gone from radical to routine. Naturally, in a field moving so fast, newbies can feel overwhelmed. Sequencing 101 is designed to provide definitions in terminology, types of platforms, workflow strategies, and current applications, to what's next? Learn about the genomic data revolution from data generation to management to analysis and interpretation.
gEnding Diagnostic Odysseysh: A Bio-IT World Podcast
Guest: ELIZABETH WORTHEY PhD, Assistant Professor, Medical College of Wisconsin
Host: KEVIN DAVIES, Editor, Bio-IT World
A team led by Liz Worthey and Howard Jacob recently published a landmark case report in which genome sequencing of an individual patient, Nicholas Volker, produced a specific diagnosis and a meaningful therapy. Since October 2010, their team at the Medical College of Wisconsin has established a comprehensive review system to end the diagnostic odysseys of other young patients.
In this exclusive podcast, recorded at the Copenhagenomics conference in June 2011, Liz Worthey discusses with Bio-IT World editor Kevin Davies the highs and lows of the Volker case, the challenges of genome data analysis, and how that experience has provided the foundation for ongoing clinical genome sequencing efforts.